Buybacks in Bloom as Life Science Tools, MDx Firms Deploy Cash

Firms may not be ready to jump head first into the M&A pool, but an acceleration in buybacks signals that they are ready to spend cash again after conserving it during the recent economic downturn.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.